.Attribute Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of individuals along with HER2+ advanced breast cancer cells and energetic or even dependable mind metastases revealed steady intracranial task as well as systemic efficiency of T-DXd.